PD-L1 expression

Programmed death-ligand 1 protein expression measured by immunohistochemistry on tumor and/or immune cells; used as a predictive marker for PD-1/PD-L1 checkpoint inhibitors in many carcinomas.

CI-BIO-00000026CD274 graph →NCIt C128554 Tumor-agnostic · 1 approval row

Also calledPD-L1 · CD274 · B7-H1 · programmed death-ligand 1 · PD-L1 TPS · PD-L1 CPS

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (1)

Pembrolizumab US FDA · Sep 4, 2014 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (10)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Lung Non-Small Cell Carcinoma	8	6	2	—	0 / 8 / 0 / 0 / 0
Malignant Neoplasm	3	1	2	—	0 / 3 / 0 / 0 / 0
Malignant Breast Neoplasm	2

Derived

Drugs with predictive evidence (7)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
PembrolizumabMonoclonal Antibody	7	7	—	B	6 / 0	Lung Non-Small Cell Carcinoma, Melanoma, Merkel Cell Carcinoma
NivolumabMonoclonal Antibody	6	6	—	B	5 / 0	Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Melanoma
AtezolizumabMonoclonal Antibody	3	3	—	B	3 / 0	Lung Non-Small Cell Carcinoma
AvelumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
DurvalumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
Radiation Therapy	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
IpilimumabMonoclonal Antibody	1	1	—	B	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (11)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–11 of 11 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD274 Expression11
Radiation Therapy	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	4	accepted	EID3000 Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamo… (full text at CIViC) PMID 28476872 · Skinner et al., 2017 · Open in CIViC	civic
Atezolizumab	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID1172 Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 ex… (full text at CIViC) PMID 26970723 · Fehrenbacher et al., 2016 · Open in CIViC	civic
Nivolumab + PembrolizumabSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID743 Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targe… (full text at CIViC) PMID 26086854 · Carbognin et al., 2015 · Open in CIViC	civic
Atezolizumab + Avelumab + Nivolumab + PembrolizumabSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID1167 Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ≥1%), had … (full text at CIViC) PMID 26918451 · Passiglia et al., 2016 · Open in CIViC	civic
Atezolizumab + Avelumab + Durvalumab + Nivolumab + PembrolizumabSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID4857 In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to bet… (full text at CIViC) PMID 28472902 · Aguiar et al., 2017 · Open in CIViC	civic
Pembrolizumab	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1733 This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation o… (full text at CIViC) PMID 27718847 · Reck et al., 2016 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID5811 PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. PMID 25891174 · Garon et al., 2015 · Open in CIViC	civic
Nivolumab	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1517 Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH f… (full text at CIViC) PMID 22658127 · Topalian et al., 2012 · Open in CIViC	civic
Ipilimumab + NivolumabCombination	Melanoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1615 A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed… (full text at CIViC) PMID 23724867 · Wolchok et al., 2013 · Open in CIViC	civic
Nivolumab + PembrolizumabSubstitutes	Melanoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID704 Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active dru… (full text at CIViC) PMID 26086854 · Carbognin et al., 2015 · Open in CIViC	civic
Pembrolizumab	Merkel Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1578 Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response ra… (full text at CIViC) PMID 27093365 · Nghiem et al., 2016 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (379)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Pembrolizumab	US FDA	Tumor-agnostic	for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. • Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. • Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. • in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. • in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. • for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. • Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 • Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. • Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. • 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

17 records matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (651)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 280 recruiting · 152 active phase 3 · 1,807 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 651 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03412877	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	recruiting	Phase 2	285	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT06623422	A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)	recruiting	Phase 3	680	Merck Sharp & Dohme LLCINDUSTRY	31	Sep 28, 2026	clinicaltrials
NCT06961006	A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)	recruiting	Phase 2	160	Merck Sharp & Dohme LLCINDUSTRY	12	Sep 28, 2026	clinicaltrials
NCT04123379	Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)	active not recruiting	Phase 2	48	Icahn School of Medicine at Mount SinaiOTHER	1	Sep 25, 2026	clinicaltrials
NCT04253964	Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy	recruiting	Phase 2	105	Wake Forest University Health SciencesOTHER	1	Sep 25, 2026	clinicaltrials
NCT04267848	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	recruiting	Phase 3	1,210	National Cancer Institute (NCI)NIH	2	Sep 25, 2026	clinicaltrials
NCT05136196	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	recruiting	Phase 2	150	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT05583708	Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer(iPRRT)	recruiting	Phase 2	18	Weill Medical College of Cornell UniversityOTHER	1	Sep 25, 2026	clinicaltrials
NCT05920356	A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)	recruiting	Phase 3	750	AmgenINDUSTRY	38	Sep 25, 2026	clinicaltrials
NCT06103864	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	recruiting	Phase 3	625	AstraZenecaINDUSTRY	24	Sep 25, 2026	clinicaltrials
NCT06170788	Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)(TroFuse-007)	recruiting	Phase 3	614	Merck Sharp & Dohme LLCINDUSTRY	26	Sep 25, 2026	clinicaltrials
NCT06312137	A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)(TroFuse-019)	recruiting	Phase 3	780	Merck Sharp & Dohme LLCINDUSTRY	31	Sep 25, 2026	clinicaltrials
NCT06385080	A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer(OrigAMI-4)	recruiting	Phase 1 / Phase 2	287	Janssen Research & Development, LLCINDUSTRY	11	Sep 25, 2026	clinicaltrials
NCT06498635	Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial	recruiting	Phase 3	306	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT06525220	A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)	active not recruiting	Phase 3	699	Merus B.V.INDUSTRY	28	Sep 25, 2026	clinicaltrials
NCT06579196	Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1	active not recruiting	Phase 1 / Phase 2	45	University of NebraskaOTHER	1	Sep 25, 2026	clinicaltrials
NCT06667908	A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)(CONVERGE)	recruiting	Phase 2	130	Johnson & Johnson Enterprise Innovation Inc.INDUSTRY	10	Sep 25, 2026	clinicaltrials
NCT06758401	This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.	recruiting	Phase 3	714	PfizerINDUSTRY	31	Sep 25, 2026	clinicaltrials
NCT06868277	A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer(ARTEMIDELung04)	recruiting	Phase 3	830	AstraZenecaINDUSTRY	27	Sep 25, 2026	clinicaltrials
NCT07222566	Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	recruiting	Phase 3	1,410	PfizerINDUSTRY	20	Sep 25, 2026	clinicaltrials
NCT07276399	A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer(OrigAMI-5)	recruiting	Phase 3	500	Janssen Research & Development, LLCINDUSTRY	22	Sep 25, 2026	clinicaltrials
NCT07360743	Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels(META-1)	recruiting	Phase 2	275	UNICANCEROTHER	1	Sep 25, 2026	clinicaltrials
NCT07476326	Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma	recruiting	Phase 1	120	Biocon Biologics UK PLCINDUSTRY	10	Sep 25, 2026	clinicaltrials
NCT03573648	Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer(ImmunoADAPT)	active not recruiting	Phase 2	33	Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER	1	Sep 24, 2026	clinicaltrials
NCT05215340	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations(TROPION-Lung08)	active not recruiting	Phase 3	740	Daiichi SankyoINDUSTRY	28	Sep 24, 2026	clinicaltrials
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	recruiting	Phase 1 / Phase 2	134	Neonc Technologies, Inc.INDUSTRY	1	Sep 24, 2026	clinicaltrials
NCT06096844	Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	recruiting	Phase 3	304	National Cancer Institute (NCI)NIH	1	Sep 24, 2026	clinicaltrials
NCT06890598	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer(SUNRAY-02)	recruiting	Phase 3	700	Eli Lilly and CompanyINDUSTRY	29	Sep 24, 2026	clinicaltrials
NCT07838974	Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older	not yet recruiting	Phase 1	40	University of Southern CaliforniaOTHER	1	Sep 24, 2026	clinicaltrials
NCT02194738	Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	active not recruiting	N/A	7,458	National Cancer Institute (NCI)NIH	3	Sep 23, 2026	clinicaltrials
NCT03899155	Pan Tumor Rollover Study	recruiting	Phase 2	1,500	Bristol-Myers SquibbINDUSTRY	38	Sep 23, 2026	clinicaltrials
NCT04062708	CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer	active not recruiting	Phase 2	38	Alliance Foundation Trials, LLC.OTHER	1	Sep 23, 2026	clinicaltrials
NCT05061550	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer(NeoCOAST-2)	recruiting	Phase 2	630	AstraZenecaINDUSTRY	12	Sep 23, 2026	clinicaltrials
NCT06357533	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations(TROPION-Lung10)	recruiting	Phase 3	675	AstraZenecaINDUSTRY	21	Sep 23, 2026	clinicaltrials
NCT06452277	A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)(SOHO-02)	recruiting	Phase 3	555	BayerINDUSTRY	36	Sep 23, 2026	clinicaltrials
NCT06561386	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%(RELATIVITY1093)	recruiting	Phase 3	1,000	Bristol-Myers SquibbINDUSTRY	31	Sep 23, 2026	clinicaltrials
NCT06618287	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	416	Bristol-Myers SquibbINDUSTRY	10	Sep 23, 2026	clinicaltrials
NCT07405164	Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)	recruiting	Phase 3	450	Merck Sharp & Dohme LLCINDUSTRY	22	Sep 23, 2026	clinicaltrials
NCT04671667	Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	recruiting	Phase 2	188	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT05696782	Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer	recruiting	Phase 2	28	Wake Forest University Health SciencesOTHER	1	Sep 22, 2026	clinicaltrials
NCT05913388	GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma	active not recruiting	Phase 2	12	Providence Health & ServicesOTHER	1	Sep 22, 2026	clinicaltrials
NCT05977907	Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).(KIEO)	active not recruiting	Phase 2	30	Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER	1	Sep 22, 2026	clinicaltrials
NCT06066138	A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT06589804	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment	recruiting	Phase 3	158	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT06712316	Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer	recruiting	Phase 2 / Phase 3	1,580	BioNTech SEINDUSTRY	22	Sep 22, 2026	clinicaltrials
NCT06772623	Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations	recruiting	Phase 1 / Phase 2	252	AbbVieINDUSTRY	15	Sep 22, 2026	clinicaltrials
NCT06875310	A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)	recruiting	Phase 3	630	Mirati Therapeutics Inc.INDUSTRY	35	Sep 22, 2026	clinicaltrials
NCT07315750	A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.	recruiting	Phase 3	555	RemeGen Co., Ltd.INDUSTRY	1	Sep 22, 2026	clinicaltrials
NCT04032418	Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer	active not recruiting	Phase 2	9	Roswell Park Cancer InstituteOTHER	1	Sep 21, 2026	clinicaltrials
NCT04464759	A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma(LIMIT)	active not recruiting	Phase 1 / Phase 2	41	Ravi Amaravadi, MDOTHER	1	Sep 21, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Atezolizumab

EU EMA

—

Urothelial carcinoma Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria). Advanced NSCLC  Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 for selection criteria).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancer (SCLC)Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1). Triple-negative breast cancer (TNBC)Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1). Urothelial carcinoma (UC) Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC: after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria). Advanced NSCLC  Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate target…

approved

Sep 20, 2017

ema

Approval rows flagged tumor-agnostic (1)

Associated cancers (10)

Drugs with predictive evidence (7)

Predictive evidence items (11)

Approvals mentioning the linked drugs (379)

Active trials (651)

Linked publications (20)